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Adult meningitis in areas of high HIV prevalence in southern 
Africa is most commonly caused by Cryptococcus neoformans.1 
Short-term mortality in the antiretroviral therapy (ART) era varies 
widely, depending on treatment modalities and resources.2 Little 
is known about the longer-term prognosis in Africa, which would 
probably be an indicator of general effectiveness of the health 
system in managing complex HIV-associated conditions. Optimal 
management of cryptococcal meningitis (CM) involves induction 
therapy with amphotericin B ± flucytosine, acute management of 
elevated cerebrospinal fluid (CSF) pressure, consolidation therapy 
with fluconazole, initiation of ART, and linkage to long-term 
outpatient care.2 We explored outcomes 2 years after an episode of 
cryptococcal meningitis in a rural area of South Africa.
Methods
Hlabisa Hospital is a 296-bed district hospital that, with 17 primary 
health care (PHC) clinics, serves 228 000 people in northern KwaZulu-
Natal. The Hlabisa HIV Treatment & Care Programme delivers ART 
at the hospital and all PHC clinics.3 This retrospective case series 
included all adult individuals (≥16yrs) with a laboratory diagnosis of 
CM, based on a positive cryptococcal antigen (CRAG) test ± positive 
India ink examination from CSF, from 1 January - 31 December 2007. 
Hospital case records, pharmacy fluconazole records, and the HIV 
programme database were consulted regarding the acute hospital 
episode and follow-up to 31 December 2009. Kaplan-Meier survival 
analysis and Cox regression were used to analyse inpatient mortality 
and associations with baseline clinical and laboratory features. To 
assess bias introduced by exclusion of individuals without hospital 
case records, characteristics of included and excluded patients were 
compared using the chi-squared (categorical variables) and Wilcoxon 
rank-sum tests (continuous variables). Ethical approval was received 
from the Hlabisa Hospital Ethics Committee.
Results
From 104 individuals,140 positive CSF CRAG tests were identified; 
74 (71.2%) with complete hospital records were included. Median age 
was 35 years (IQR 30 - 44); 47.3% were male; 47 (63.5%) individuals 
were known HIV-infected at hospital admission, and 13 (17.6%) 
were on ART. Median CD4 cell count (N=45) was 49 cells/μl (IQR 
16 - 86). The 74 patients most commonly presented with: headache 
(82.4%), fever (37.8%), vomiting (35.1%), and reduced conscious 
level (33.8%). Sixty-seven (90.5%) of the 74 samples were positive on 
India ink examination; median CSF white blood cell (WBC) count 
was 20 cells/ml (IQR 4 - 56), and 22 (29.7%) had a WBC count <5/
ml. Only 26 patients (35.1%) received amphotericin B, and only 6 
received at least 14 days. Repeat therapeutic lumbar puncture was 
uncommon, documented in only 11 patients (14.9%).
Inpatient mortality was 40.5% (30/74), all deaths occurring within 
30 days of admission. The inpatient mortality rate was 2.99 per 100 
person-days (95% CI 2.09 - 4.28). Allowing for age, sex, CSF WBC 
count, amphotericin B treatment, CD4 cell count and ART, inpatient 
mortality was significantly associated with reduced conscious level at 
presentation (aHR 3.09, 95% CI 1.30 - 7.33) and with the presence of 
headache (aHR 0.33, 95% CI 0.13 - 0.87).
Forty-four patients survived to hospital discharge. Thirty-five 
of these (35/44) (79.5%) were confirmed HIV-infected by time of 
discharge (2 were counselled but refused testing; for 7 there was 
no documentation of counselling and testing). On discharge, all 
44 were prescribed fluconazole, of whom 12 (27.3%) also received 
ART (5 on ART at admission; 7 initiated ART during admission). 
Fig. 1 illustrates events following hospital discharge; 6 patients 
were re-admitted with cryptococcal meningitis, of whom 3 died in 
hospital. Only 9/44 (20.5%) collected further fluconazole after the 
consolidation phase, and 9/32 (28.1%) discharged on fluconazole Corresponding author: R Lessells (rlessells@africacentre.ac.za)
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Poor long-term outcomes for cryptococcal meningitis in rural 
South Africa
Richard J Lessells, Portia C Mutevedzi, Tom Heller, Marie-Louise Newell
Objectives. To explore linkage to and retention in HIV care after an 
episode of cryptococcal meningitis (CM) in rural South Africa.
Design. A retrospective case series of adult individuals (≥16 years 
old) with laboratory-confirmed CM from January - December 
2007 at Hlabisa Hospital – a district hospital in northern KwaZulu-
Natal.
Outcome measures. Inpatient mortality and associated risk factors 
were analysed. The proportion alive and on antiretroviral therapy 
(ART) at 2 years was determined by linkage to the HIV treatment 
programme.
Results. One hundred and four individuals were identified with 
laboratory diagnosis of CM; 74/104 (71.2%) with complete records 
were included in the analysis. Inpatient mortality was high (40.5%) 
and was significantly associated with reduced conscious level (aHR 
3.09, 95% CI 1.30 - 7.33) and absence of headache (aHR 0.33 for 
headache, 95% CI 0.13 - 0.87). Only 8 individuals (10.8% of all 
study subjects) were alive and receiving ART 2 years after the CM 
episode.
Conclusions. Long-term outcomes of CM are poor in routine 
practice. Interventions to strengthen linkage to HIV treatment and 
care and continuation of secondary fluconazole prophylaxis are 
critical.
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alone subsequently initiated ART. Only 8 (10.8% of all subjects, 95% 
CI 8.7 - 12.8) were alive and receiving ART 2 years after the CM 
episode. For the 10 confirmed deaths post-discharge, the median 
time to death was 133 days (IQR 43 - 230).
There was no evidence that included patients (N=74) differed from 
those excluded (N=30) in terms of sex (p=0.73), age (p=0.13), CSF 
protein (p=0.35), CSF glucose (p=0.31) or CSF lymphocyte count 
(p=0.26).
Discussion
These data from routine practice in a rural health district show 
poor long-term outcomes and highlight the challenges faced by 
overburdened health services in delivering comprehensive HIV care 
in high-prevalence settings. The short-term mortality is comparable 
with data from similar settings,4,5 but higher than reports from 
clinical trials or tertiary hospitals.6-10 About 1 in 10 of our patients 
were known to be alive on ART at 2 years, compared with: 60% at 
12 months in a clinical trial in Cape Town;7 40.9% at 12 months in a 
cohort in Uganda;9 36.7% at 6 months in a Ugandan clinical trial;10 
and 27% at 3 years in a trial in Zimbabwe.11 Inpatient mortality was 
associated with more severe disease (reduced conscious level and 
absence of headache), as also suggested in a neighbouring hospital 
in KwaZulu-Natal.5 High fungal burden is associated with mortality; 
our high rate of India ink positivity and reduced consciousness 
suggest advanced disease at presentation.12 Sub-optimal induction 
therapy and management of CSF pressure might have contributed 
to high inpatient mortality, although we could not confirm this. 
Amphotericin B treatment was uncommon, mainly owing to drug 
supply problems, in accordance with national-level data showing 
that more than half of CM cases receive sub-optimal induction 
treatment.13
Not all patients had their HIV status confirmed during admission, 
possibly owing to patient refusals, health care worker uncertainty 
about consent for confused or unconscious patients, or inadequate 
provision of counselling and testing services. The most striking 
finding was the high rate of loss to follow-up after hospital discharge; 
almost half were not seen again, which suggests poor linkage between 
hospital inpatient services and PHC clinics providing ongoing 
HIV care and treatment. Continuation of fluconazole after the 
consolidation phase was also uncommon, similar to other findings 
in South Africa.14,15 While some patients might have accessed 
fluconazole and ART elsewhere, the majority probably died.
There are limitations to this analysis, including those inherent 
in retrospective investigations. Retrieval of hospital records was 
incomplete, although we found no evidence that bias was introduced 
by excluding those without case records. Our numbers were too 
small to explore factors associated with long-term survival. Since 
this study, aspects of care have been improved: improved supply of 
amphotericin B, clear protocols for managing CSF pressure, enhanced 
HIV counselling and testing service for inpatients, and better linkage 
systems between hospital and PHC clinics. However, numerous 
challenges remain with the increasing numbers of CM cases in South 
Africa.16 Practical, implementable local care pathways, that encompass 
acute management and early post-discharge community support and 
enhanced clinical follow-up, must be developed and evaluated. By 
strengthening health systems, we can realise the full benefits from the 
scale-up of comprehensive HIV treatment and care.
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*Includes 5 individuals not seen after hospital discharge.
†Includes 15 individuals not seen after hospital discharge.
Fig. 1. Study subject interventions and outcomes up to 31 December 2009 
(N=74).
